Galectin Therapeutics (OTC:GALT) used to be traded at levels around $1.25. In late July the price plunged and seemed to be declining until Sept. 7 when things changed.
On Sept. 7, GALT hit a low of $0.81. That day the company announced it would present a corporate update at the Rodman & Renshaw Healthcare Conference. The very next day GALT bounced up and yesterday it closed at the $1 mark.[BANNER]
The conference was held on Tuesday, Sept. 13. A webcast of the presentation is available here.
There has been a number of developments around GALT that could be seen as positive. The company has enough financing to operate for a while.
Unfortunately, the time at which GALT could potentially finance its operations from revenues is still in the future.
As of the time of this writing, GALT is trading at $1.03. There is no telling how things will go in the long run for GALT, but if the company successfully executes its plans and commercializes its products at some point, it could generate substantial revenues.
